

# Index

## A

- AAA+ chaperones, 21–22
- AAA+ proteases, 20–21, 167–168
- ABCA4 mutations, 300–301
- Aggregation
  - adaptation of proteostasis network to ameliorate disease, 316–329
  - adapting proteostasis to ameliorate diseases, 307–333
  - aggregate clearance by asymmetric damage inheritance, 22–23
  - in  $\alpha$ 1-antitrypsin deficiency, 182–184
  - Alzheimer's disease  $A\beta$  aggregates, 76–78
  - biological regulation of, 7–9
  - chaperones and, 35–36, 114–115
  - chemical regulation of, 9–10
  - chemical strategies to ameliorate disease, 329–333
  - as concentration-dependent process, 105
  - disaggregation, small heat shock proteins and, 22
  - disease and, 2–4
  - energy landscape, 104, 312
  - generic view of
    - biological regulation of aggregation, 7–9
    - chemical regulation of aggregation, 9–10
    - kinetics of aggregation, 4–6
    - protein solubility, key role of, 4, 5
    - thermodynamics of aggregation, 6–7
  - Huntington's disease, inclusion bodies in, 215–224
  - Parkinson's disease
    - $\alpha$ -synuclein, 238
    - parkin, 240–241
  - reversing by AAA+ chaperones, 21–22
- Aging
  - autophagy, 74–75
  - diseases of misfolding, 76
  - evolutionary tradeoffs, 78
  - heat shock response, 72–73
  - hypoxia response, 73
  - mitochondrial quality control, 173–174
  - neurodegenerative disease, 76–78
  - pathways that influence, 67–69
    - dietary restriction, 67, 68, 71
    - electron transport chain (ETC), 68
    - insulin-IGF-1-like signaling pathway (IIS), 67–69, 71
  - proteasomal degradation, 75–76
  - protein degradation, 74
    - protein folding, 71–72
    - protein trafficking, 74
    - proteostasis collapse, 67–79
    - proteostasis importance in, 69–70
    - role in Huntington's disease, 213–214
    - translation rate and, 70–71
    - ubiquitin-proteasomal system (UPS), 75–76
    - unfolded protein response (UPR), 73
- ALIS, 38
- $\alpha$ 1-antichymotrypsin mutation, 190
- $\alpha$ 1-antitrypsin deficiency, 181–192
  - activating proteolytic degradation by lysosome, 329
  - carcinogenesis, 181–192
  - cellular response pathways and ATZ accumulation in ER, 188–189
  - determinants of tissue-specific damage, 184–185
  - genetic and environmental modifiers, 185
  - hepatic fibrosis, 181–192
  - mitochondrial dysfunction in liver disease, 184
  - other serinopathies compared, 189–192
  - overview, 181–182
  - proteasomal and autophagic pathways as modifiers of tissue damage, 185–188
  - protein aggregation role in tissue damage, 182–184
  - therapeutic strategies, 189
  - variations in clinical disease among homozygotes, 185
- $\alpha$ -synuclein
  - described, 237
  - misfolding and aggregation, 238
  - posttranslational modifications, 238–239
  - protein sequence, schematic of, 242
  - variants, 237–238
- ALS. *See* Amyotrophic lateral sclerosis (ALS)
- Alzheimer's disease, 195–206
  - $A\beta$  aggregates, detoxification of, 76–78
  - $A\beta$  generation by regulated proteolysis of precursor protein, 197–199
  - genetics of, 199
  - genotype-to-phenotype relationships in familial AD, 199–201
  - model in *C. elegans*, 76–78
  - mouse models, genetically engineered, 78, 201–203
  - overview, 195–196
  - protein chemical nature of diagnostic brain lesions, 196–197
  - retinal involvement, 303

## Index

- Alzheimer's disease (*Continued*)  
  synaptic form and function perturbation by  
  prefibrillar forms of A $\beta$ , 203–204  
  therapeutic opportunities from mechanistic  
  study of A $\beta$ , 204–206
- Amyloid  $\beta$ -proteins (A $\beta$ ), 196–206
- Amyloid plaques/filaments  
  in Alzheimer's disease, 195–206  
  prion protein (PrP), 260, 266
- Amyotrophic lateral sclerosis (ALS), 246–253  
  fused in sarcoma/translocated in liposarcoma  
  (FUS/TLS), 250–253  
  overview, 236–237  
  RNA quality control and, 249  
  SOD1  
    in familial ALS, 246–248  
    in sporadic ALS, 248–249  
  TDP-43, 249–250
- Antithrombin mutations, 191
- Apoptosis, ER stress-induced, 151–152
- APP ( $\beta$ -amyloid precursor protein), 197–200,  
  202–204
- ATF6, 148–150
- ATP-dependent proteolysis in mitochondrial matrix,  
  165–167
- Autophagy  
  aging and, 74–75  
  in  $\alpha$ 1-antitrypsin deficiency, 186–187  
  chaperone-mediated (CMA), 50–52  
  chemical modulation of clearance, 55  
  clearance and, 49–55  
  described, 49–50  
  macroautophagy, 51–52, 74–75  
  microautophagy, 52  
  mitophagy, 172  
  pathophysiology of quality control through, 53–55  
  pathway characteristics, 50–52  
  pathway of misfolded protein degradation, 37  
  physiological functions of, 52–53
- B**
- Bacteria. *See* Prokaryotes
- Bestrophin 1, 301
- $\beta$ -amyloid precursor protein (APP), 197–200, 202–204
- Bip, 123–124, 148–149
- Bovine spongiform encephalopathy (BSE), 263–264
- Bunina bodies, in amyotrophic lateral sclerosis (ALS),  
  236
- C**
- C1 inhibitor mutations, 191
- CAG expansion, in Huntington's disease, 76, 212–215
- Calcium  
  balance, endoplasmic reticulum, 135–136  
  mitochondrial permeability transition, 155  
  signaling at mitochondrial-associated membranes  
  (MAM), 152–154
- Calnexin, 123, 154
- Calreticulin, 123, 154
- Carbamazepine, 189, 190
- Carcinogenesis, in  $\alpha$ 1-antitrypsin deficiency, 181–192
- CFTR (cystic fibrosis transmembrane conductance  
  regulator), 281–282, 284–293,  
  325–326
- Chaperone-mediated autophagy (CMA), 50–52
- Chaperones  
  AAA+, 21–22  
  aging and protein folding, 71–72, 114–115  
  altering chaperone-cochaperone interactions to  
  enhance degradation, 319–320  
  autophagy and, 50–52  
  balancing between folding, degradation, and  
  aggregation, 35–36  
  chaperonins, 109–111  
  classes of, 35–36, 106  
  CLIPS (chaperones linked to protein synthesis), 35  
  co-chaperones, 123–124, 319–320  
  cytosolic machinery, 106  
  DnaK system, 15  
  GroE system, 15–16, 109–111  
  heat shock response and, 18  
  HSP70 family, 107–109  
  Hsp90 system, 110, 111–112  
  in Huntington's disease, 217–219  
  at mitochondrial-associated membranes (MAMs),  
  154–155  
  mitochondrial quality control and, 162, 163–165  
  networks, 87–88  
  overview, 105–106  
  pharmacologic, 329–330  
  in prokaryotes, 15–16  
  quality control and, 48  
  ribosome-associated, 106, 107, 314–315  
  specialization, 95–96  
  stress responses, 72, 112–114
- Chaperones linked to protein synthesis (CLIPS), 35
- Chaperonins, 109–111
- Chronic obstructive pulmonary disease (COPD), in  
   $\alpha$ 1-antitrypsin deficiency, 184–185
- Chronic wasting disease (CWD), 263–264
- CJD. *See* Creutzfeldt–Jakob disease
- Clearance mechanisms  
  autophagy, 49–55  
    chaperone-mediated (CMA), 52  
    chemical modulation, 55  
    described, 49–50  
    macroautophagy, 51–52  
    microautophagy, 52  
  pathophysiology of quality control through,  
  53–55

- pathway characteristics, 50–52
- physiological functions of, 52–53
- integration of, 47–62
- intracellular, 48–49
- ubiquitin/proteasome system (UPS), 55–61
  - 26S proteasome, 59
  - chemical modulation, 61
  - components, 56
  - decoding ubiquitination at the proteasome, 58–59
  - described, 55–56
  - pathophysiology of quality control, 60
  - ubiquitination language, 57–58
  - ubiquitin conjugation, 56–57
- CLIPS (chaperones linked to protein synthesis), 35
- ClpP protease, 166–167
- Co-chaperones, 123–124, 319–320
- COPD (chronic obstructive pulmonary disease), in
  - $\alpha$ 1-antitrypsin deficiency, 184–185
- Creutzfeldt–Jakob disease (CJD), 261, 263
  - familial (fCJD), 261, 263
  - iatrogenic (iCJD), 263
  - sporadic (sCJD), 261
  - variant (vCJD), 263
- CWD (chronic wasting disease), 263–264
- Cystatin C, 236
- Cystic fibrosis, 281–293
  - pathological triad, 281, 282
  - proteostasis network, 324–326
    - CFTR biology and, 285–287
    - emergent properties as guide for rescue of misfolding disease, 293
    - as framework for disease management, 282–285
    - management of vCFTR functions by, 290
    - model systems, 289–291
    - therapeutics and, 287–291
  - as systems disease, 281–282
  - therapeutics
    - new targets affecting restoration of tissue function, 292–293
    - proteostasis network and, 287–291
  - trafficking, 284–285
- Cystic Fibrosis Foundation Therapeutics modulator library, 287
- Cystic fibrosis transmembrane conductance regulator (CFTR), 281–282, 284–293, 325–326
- Cytosolic stress, 112
- D**
- DAF-16, 77
- DALIS, 38
- DegP, 24–25
- Degradation
  - aging and, 74, 75–76
  - altering chaperone-cochaperone interactions to enhance, 319–320
  - chaperones and, 35–36
  - endoplasmic reticulum and (*see* ER-associated degradation)
  - pathways of misfolded protein, 36–37
  - retrotranslocation and, 132
- Deubiquitinating enzymes (DUBs), 59
- Diabetes, 78, 326–327
- Dietary restriction pathway, 67, 68, 71
- Disaggregation, small heat shock proteins and, 22
- Disulfide bond formation, 124–125
- DJ-1 gene, 246
- DnaK system, 15, 18–20
- Dsb proteins, 25–26
- DUBs (deubiquitinating enzymes), 59
- E**
- E3 ligases, 37, 57, 126
- EDEM proteins, 131–132, 133
- Electron transport chain (ETC) pathway, 68
- ELOVL4 mutations, 300
- Endoplasmic reticulum
  - $\alpha$ 1-antitrypsin mutant protein accumulation in, 188–189
  - calcium and mitochondrial permeability transition, 155
  - cell survival and death, role in, 147–156
  - homeostasis, 133–136
    - calcium balance, 135–136
    - redox, 134–135
  - mitochondria interactions, 152–153
  - posttranslational modifications, 123–125
    - disulfide bond formation, 124–125
    - glycosylation, 123
  - protein folding and quality control in, 121–137
  - protein folding by chaperones and co-chaperones, 123–124
  - specialized compartments within, 136
  - therapeutics and, 136–137
  - translation of ER-targeted proteins, 121, 123
  - unfolded protein response (UPR), 148–151
  - up-regulation of proteostasis network by calcium increase, 328–329
- Endoplasmic reticulum secretory compartment, proteostasis challenges of, 321–322
- Energy landscape, of protein folding and aggregation, 104, 310, 312
- Environmental stress response, 35
- ER-associated degradation (ERAD), 125–133
  - motif names, table of, 130–131
  - pathway of misfolded protein degradation, 37
  - pathways, 133
  - proteins, table of, 128–129

## Index

- ER-associated degradation (*Continued*)  
  recognition and targeting, 125, 127, 131–132  
  retrotranslocation and degradation, 132–133
- ERdj proteins, 123–124
- ER stress, 147–156  
  death response, 151–152  
  unfolded protein response (UPR), 73
- Exotic ungulate encephalopathy, 263
- Eye  
  protein misfolding and retinal degeneration,  
    297–304  
  structure and function, 297–298
- F**
- Fabry disease, 329
- Familial encephalopathy with neuroserpin inclusion  
  bodies (FENIB), 191
- Fatal familial insomnia (FFI), 261, 263
- Fibulin-3, 301
- FoldEx, 285
- Folding. *See* Protein folding
- FOXO signaling, 316–318
- FtsH protease, 21
- Fungal prions, 260, 271
- Fused in sarcoma/translocated in liposarcoma  
  (FUS/TLS), 250–253
- G**
- Gain-of-function disorders  
   $\alpha$ 1-antitrypsin deficiency, 181–192, 329  
  leucine-rich repeat kinase-2 (LRRK2) mutations,  
    243–244  
  serinopathies, 189–192
- Gaucher's disease, 329–330
- Gene therapy, for retinal degenerations, 304
- Genetic variation, natural, 96–97
- Gerstmann–Stäussler–Scheinker (GSS) syndrome, 261
- GroE system, 15–16, 18–19, 109–111
- Guanabenz, 327
- H**
- Heat shock factor 1 (HSF1), 72, 76–77, 88–90, 94,  
  96, 113–114, 313, 314
- Heat shock proteins  
  disaggregation and, 22  
  Hsp40 family, 123–124  
  Hsp60, 165  
  HSP70 family, 107–109  
  Hsp78, 165  
  Hsp90 system, 110, 111–112, 320–321  
  transcriptional regulation of, 113, 114
- Heat shock response  
  activating to ameliorate degeneration of postmitotic  
    tissue, 316, 318  
  aging and, 72–73  
  cytosolic/nuclear compartment, 313–316  
  HSF axis, 112–114  
  Hsp90 inhibitors to induce, 320–321  
  proteasome inhibitors and, 327–328
- Heparin cofactor II mutations, 190
- Hepatic fibrosis, in  $\alpha$ 1-antitrypsin deficiency,  
  181–192
- HIF1, 73
- Homeostasis. *See also* Proteostasis  
  endoplasmic reticulum, 133–136  
  protein  
    integrating strategies in prokaryotes, 13–26  
    overview of, 3  
    protein solubility, key role of, 4, 5
- HSF-1. *See* Heat shock factor 1
- Hsp40 family, 123–124
- Hsp60, 165
- HSP70 family, 107–109
- Hsp78, 165
- Hsp90 system, 110, 111–112, 320–321
- HtrA2 protease, 168
- Huntington, George, 211
- Huntington's disease, 211–227  
  aging, role of, 213–214  
  correlations to protein accumulation, 215  
  evidence of a proteopathy, 214–215  
  genetic determinants  
    of symptom onset and disease progression,  
      212–213  
    of symptom profile and neuropathy, 213  
  genotype–phenotype correlations, clinical overview  
    of, 212–214  
  history, 211  
  HTT aggregation, 215  
  inclusion body  
    formation, 215  
    as mismatch of protein production and  
      clearance, 215–217  
    as regulated mechanism to cope with misfolded  
      proteins, 221–224  
    significance to neurodegeneration, 219–221  
  integrated view of misfolding and  
    neurodegeneration in, 224–227  
  misfolding leading to neurodegeneration,  
    225–227  
  network for protein homeostasis, 224–225  
  protein folding and molecular chaperones, 217–219  
  proteostasis and, 214–224
- Huttingin (Htt) protein. *See* Huntington's disease
- Hypoxia response, aging and, 73
- I**
- Inclusion bodies in Huntington's disease, 215–224
- Insulin growth factor-1 signaling, 316–319

- Insulin-IGF-1-like signaling pathway (IIS)  
  pathway, 67–69, 71
- IPOD, 38–39
- IRE1, 148–150
- J**
- JUNQ, 38–39
- K**
- Kinetics of protein aggregation, 4–6
- Kinetic stabilizers, 330–333
- Kuru, 263
- L**
- Leucine-rich repeat kinase-2 (LRRK2) mutations,  
  243–244
- Levinthal paradox, 104
- Lewy bodies, Parkinson's disease, 236–239, 241, 246
- Life cycle, protein, 70
- Lon protease, 20–21, 165–166
- Lou Gehrig's disease. *See* Amyotrophic lateral sclerosis  
  (ALS)
- LRRK2 (leucine-rich repeat kinase-2) mutations,  
  243–244
- Lung injury, in  $\alpha$ 1-antitrypsin deficiency, 184–185
- Lysosomal enzymes, pharmacologic chaperones to  
  prevent misfolding and degradation of, 329–  
  330
- Lysosomal storage diseases, 322–324, 329
- Lysosomes, 49–55, 329. *See also* Autophagy
- M**
- Macroautophagy, 51–52, 74–75
- Mad cow disease, 263
- Malattia Leventinese, 301
- MAM (mitochondrial-associated membranes),  
  152–155
- Manganese superoxide dismutase, 165
- Megsin, 191–192
- Metabolic syndrome, 78, 326
- Metastability of human proteome, 7
- Mice, transgenic  
  Alzheimer's disease models, 201–203  
  prions, 264–265
- Microautophagy, 52
- Misfolding of proteins  
  AAA+ protease removal, 20–21  
  adaptation of proteostasis network to ameliorate  
  disease, 316–329  
  adapting proteostasis to ameliorate diseases,  
  307–333  
  in Alzheimer disease, 303  
  causes and consequences of, 34–35
- cellular strategies in protein quality control,  
  33–42
- chemical strategies to ameliorate disease,  
  329–333
- cystic fibrosis transmembrane conductance regulator  
  (CFTR), 281–282, 284–293
- generic view of, 1–10  
  aggregation and disease, 2–4  
  biological regulation of aggregation, 7–9  
  chemical regulation of aggregation, 9–10  
  kinetics of aggregation, 4–6  
  metastability, 7  
  protein folding and misfolding, 2  
  protein solubility in homeostasis, key role of, 4  
  thermodynamics of aggregation, 6–7
- Huntington's disease, 221–227
- Parkinson's disease, 303  
   $\alpha$ -synuclein, 238  
  parkin, 240–241
- in prokaryotes, 13–14
- retinal degeneration and, 297–304
- serpins, 183
- SOD1 (superoxide dismutase-1), 246–248
- stress of, 85–98
- unified view of, 10
- Mitochondria  
   $\alpha$ 1-antitrypsin deficiency and liver disease, 184
- endoplasmic reticulum interactions, 152–153
- evolution of, 161
- function of, 161–162
- fusion, proteolytic control of, 170–172
- mitophagy, 172
- outer membrane proteins, turnover of, 168–170
- permeability transition, 155
- proteases, 165–168  
    AAA, 167–168  
    ClpP, 166–167  
    HtrA2, 168  
    Lon, 165–166  
    Oma1, 168
- quality control, 161–174
- reticular networks, 162
- Mitochondrial-associated membranes (MAMs),  
  152–155
- Mitochondrial quality control, 161–174  
  in aging and disease, 173–174
- chaperones, 162, 163–165
- proteases and, 165–168  
    ATP-dependent proteolysis in mitochondrial  
    matrix, 165–167
- proteolytic systems, 166
- QC across the inner membrane, 167–168
- QC in intermembrane space, 168
- proteolytic control of fusion and mitophagy,  
  170–172
- surveillance mechanisms, 161–174

## Index

- Mitochondrial quality control (*Continued*)  
ubiquitin/proteasome system (UPS), 162, 168–170  
unfolded protein response (UPR),  
mitochondria-specific, 172–173
- Mitophagy, 172
- Molecular chaperones. *See* Chaperones
- Movement disorders, 235–253  
amyotrophic lateral sclerosis (ALS), 246–253  
overview, 235–237  
Parkinson's disease, 237–246
- MtHsp70, 164–165
- N**
- Neurodegenerative disease  
aging, 76–78  
Alzheimer's disease, 195–206  
amyotrophic lateral sclerosis (ALS), 246–253  
Huntington's disease, 211–227  
Parkinson's disease, 237–246
- Neurofibrillary tangles, in Alzheimer's disease, 195, 196–197
- Neurologic disorders of movement, 235–253  
amyotrophic lateral sclerosis (ALS), 246–253  
overview, 235–237  
Parkinson's disease, 237–246
- Neuroserpin gene mutations, 191
- Nucleation-elongation-fragmentation model of fibril formation, 5, 6
- O**
- Oligosaccharyltransferase, 123
- Oma1 protease, 168
- OPA1 (Optic atrophy 1), 169–172
- Outer membrane proteins (OMPs), 24
- Oxidative stress, 19–20
- P**
- Parkin, 172  
described, 239–240  
postmortem evaluation of stability, 242–243  
posttranslational modifications, 241–242  
proteostasis, 243  
stability, impact of disease-linked truncations and mutations on, 240  
stress-induced misfolding and aggregation, 240–241
- Parkinson's disease, 237–246  
 $\alpha$ -synuclein  
described, 237  
misfolding and aggregation, 238  
posttranslational modifications, 238–239  
protein sequence, schematic of, 242  
variants, 237–238
- DJ-1 gene, 246  
leucine-rich repeat kinase-2 (LRRK2) mutations, 243–244  
mitophagy, 172  
overview, 236–237  
parkin, 172  
described, 239–240  
postmortem evaluation of stability, 242–243  
posttranslational modifications, 241–242  
proteostasis, 243  
stability, impact of disease-linked truncations and mutations on, 240  
stress-induced misfolding and aggregation, 240–241  
pathway for, 245  
PINK1 gene, 244  
retinal involvement, 303  
UCH-L1, 244–246
- PDI family proteins, 124
- Periplasmic quality control system, 24–26
- PERK, 148–151, 326–327
- Pharmacologic chaperones, 329–330  
in cystic fibrosis, 287–288  
for photoreceptors, 303
- Phosphodiesterase 6 (PDE6) mutations, 300
- Photoreceptors, unfolded protein response (UPR) in, 299–301
- Pick's disease, 272
- PINK1, 172, 244
- PME (progressive myoclonus epilepsy), 191
- Polyglutamine (polyQ) expansion, in Huntington's disease, 76, 212–221, 224–227
- Polymorphisms, 96–97
- Postmitotic tissue degeneration, 316, 318, 330–333
- Posttranslational modifications, 123–125  
disulfide bond formation, 124–125  
glycosylation, 123  
Parkinson's disease  
 $\alpha$ -synuclein, 238–239  
parkin, 241–242
- Presenillin 1 and presenillin 2, 199, 201, 202
- Prion-like diseases, 272–273
- Prions, 259–273  
amyloid, 260, 266  
bioluminescence imaging, 266, 267  
characteristics of mammalian, 272  
de novo generation of, 268–271  
diseases  
in animals, 263–264  
in humans, 261, 263  
table of, 262  
therapeutics for, 273  
formation, cell biology of, 268  
fungal, 260, 271  
prion-like diseases, 272–273  
protein isoforms, 259–260

- PrP genes, 260–261, 262
  - replication, 265–266
  - strains, 271–272
  - structural features of PrP, 268, 269, 270
  - transgenic mice, 264–265
  - Progressive myoclonus epilepsy (PME), 191
  - Prokaryotes
    - AAA+ chaperones, reversing aggregation
      - by, 21–22
    - AAA+ proteases, removal of misfolded proteins
      - by, 20–21
    - adjusting quality control networks to environmental stress, 16–18
    - aggregate clearance by asymmetric damage
      - inheritance, 22–23
    - asymmetric damage inheritance, 22–23
    - challenges to quality control systems during stress, 18–20
    - disaggregation, heat shock proteins and, 22
    - misfolding and quality control systems, 13–14
    - polar aggregate deposition in *E. coli*, 23
    - protein folding
      - chaperone systems, 15–16
      - ribosome-bound trigger factor and, 14–15
    - stress responses, regulation of, 16–18
  - Proteases
    - AAA+, 20–21, 167–168
    - ClpP, 166–167
    - HtrA2, 168
    - Lon, 20–21, 165–166
    - mitochondria, 165–168
    - Oma1, 168
  - Proteasomal degradation
    - aging, 75–76
    - pathway in  $\alpha$ 1-antitrypsin deficiency, 185–186
  - Proteasome
    - activating degradation to reestablish cytosolic proteostasis, 319
    - decoding ubiquitination at, 58–59
    - inhibitors and heat shock response, 327–328
    - 26S, 59
  - Protein folding. *See also* Misfolding of proteins
    - aging and, 71–72
    - in cytoplasm, 103–115
      - chaperones, 106–114
      - energy landscape, 104
      - heat shock response and, 103–115
      - overview, 103–115
    - in endoplasmic reticulum, 121–137
      - energy landscape, 104, 310, 312
      - Levinthal paradox, 104
      - molecular chaperones, 105–114 (*see also* Chaperones)
      - overview, 309–313
      - in prokaryotes
        - chaperone systems, 15–16
        - ribosome-bound trigger factor and, 14–15
  - Protein quality control
    - causes and consequences of misfolding, 34–35
    - cellular strategies in, 33–42
    - chaperones and, 35–36
    - compartments in eukaryotic cells, 39
    - model for misfolded protein toxicity in
      - amyloidogenic disease, 41
    - pathways of misfolded protein degradation, 36–37
    - protein sequestration, advantages of, 40
    - role in cellular integrity, 33–34
    - spatial organization of pathways, 37–40
  - Protein sequestration, advantages of, 40
  - Protein trafficking, aging and, 74
  - Proteome
    - maintaining functional, 87–91
      - chaperone networks, 87–88, 89
      - stress response, role of, 88–90
    - variation, natural genetic, 96–97
  - Proteostasis
    - activating protein degradation to reestablish cytosolic, 319
    - aging as event of collapse in, 67–79
    - challenges of the endoplasmic reticulum secretory compartment, 321–322
    - in extracytoplasmic compartments, 24–26
    - Huntington's disease and, 214–224
    - organismal
      - chaperone specialization, 95–96
      - nonautonomous regulation, 93–94
    - pathways, 90
    - quality control of mitochondrial, 161–174
    - regulators in cystic fibrosis, 288
    - stress-response signaling to maintain in the endoplasmic reticulum, 322
  - Proteostasis network
    - adaptation to ameliorate disease, 316–329
    - components of, 282–283
    - in cystic fibrosis, 281–293, 324–326
      - CFTR biology and, 285–287
      - emergent properties as guide for rescue of misfolding disease, 293
      - framework for disease management, 282–285
      - management of vCFTR functions by, 290
      - model systems, 289–291
      - therapeutics and, 287–291
    - diabetes/metabolic syndrome alleviation and, 326
    - matching misfolded protein load, 92
    - up-regulation of by ER calcium increase, 328–329
- Q**
- Quality control
    - autophagy, 53–55
    - cellular strategies in protein QC, 33–42

## Index

### Quality control (*Continued*)

- in endoplasmic reticulum, 121–137
- of mitochondrial proteostasis, 161–174
- overview, 85–87
- prokaryotes
  - adjusting networks to environmental stress, 16–18
  - challenges during stress conditions, 18–20
  - in periplasm, 24–26
  - protein misfolding and, 13–14
- RNA and ALS, 249
- Ubiquitin/proteasome system (UPS), 60, 162, 168–170

## R

- Reactive oxygen species (ROS), 165
- Redox homeostasis, endoplasmic reticulum, 134–135
- Retina, structure and function of, 297–298
- Retinal degeneration, protein misfolding and, 297–304
  - diseases
    - Alzheimer disease, 303
    - Parkinson's disease, 303
    - retinitis pigmentosa, 302
    - role of misfolded proteins, 301–302
    - Stargardt's disease, 302
    - systemic diseases, 303
  - therapeutic strategies for correction of misfolding, 303–304
  - unfolded protein response (UPR), 298–301
    - ABCA4 mutations, 300–301
    - ELOVL4 mutations, 300
    - mild response as protective, 301
    - phosphodiesterase 6 (PDE6) mutations, 300
    - in photoreceptors, 299–301
    - in retinal pigment epithelium (RPE), 301
    - retinoschisin, 301
    - rhodopsin mutations, 299–300
- Retinal pigment epithelium (RPE)
  - structure and function, 298
  - unfolded protein response (UPR), 301
- Retinitis pigmentosa, 302
- Retinoschisin, 301
- Retrotranslocation, 132
- Rhodopsin mutations, 299–300
- Ribosome-associated chaperones, 106, 107, 314–315
- RNA quality control, amyotrophic lateral sclerosis (ALS) and, 249
- RNA thermometers, 17–18
- ROS (reactive oxygen species), 165
- ROSE element, 18

## S

- Scrapie, 264
- Sequestration

- advantages of protein, 40
- of aggregates at polar sites in *E. coli*, 23
- Serpinoopathies
  - $\alpha$ 1-antichymotrypsin mutation, 190
  - $\alpha$ 1-antitrypsin deficiency, 181–192
  - antithrombin mutations, 191
  - C1 inhibitor mutations, 191
  - heparin cofactor II mutations, 190
  - neuroserpin gene mutations, 191
- Serpins
  - folding and misfolding, 183
  - megsin, 191–192
- SOD1 (superoxide dismutase-1), in ALS, 41, 246–249
  - familial, 246–248
  - sporadic, 248–249
- Solubility, role in homeostasis, 4, 5
- Stargardt's disease, 302
- Stress, cytosolic, 112
- Stress-induced misfolding and aggregation of parkin, 240–241
- Stress-induced mitochondrial hyperfusion (SIMH), 163
- Stress of misfolding of proteins, 85–98
- Stress response. *See also* Unfolded protein response (UPR)
  - HSF axis, 112–114
  - maintaining functional proteome, role in, 88–91
- Stress responses
  - in bacteria
    - challenges to quality control systems during stress, 18–20
    - regulation of, 16–18
  - chaperones and, 72

## T

- Tau, 196–197, 199, 205
- TDP-43, 249–250
- Temperature-responsive RNAs, 17–18
- Thermodynamics of protein aggregation, 6–7
- TOR, 71
- Transcriptional regulation of heat shock proteins, 113, 114
- Translational attenuation, 326–327
- Translation of ER-targeted proteins, 121, 123
- Translation rates, 70–71
- Transmissible mink encephalopathy (TME), 263
- Transthyretin amyloidogenesis, 330–333
- TriC/CCT $\gamma$ , 111, 315
- Trigger factor, 14–15, 106, 107
- 26S proteasome, 59

## U

- Ubiquitination
  - conjugation, 56–57
  - decoding at the proteasome, 58–59



- deubiquitinating enzymes (DUBs), 59
  - language, 57–58
  - Ubiquitin/proteasome system (UPS), 55–61
    - aging and, 75–76
    - chemical modulation, 61
    - clearance mechanisms, 55–61
    - components, 56
    - decoding ubiquitination at the proteasome, 58–59
    - described, 55–56
    - mitochondrial quality control and, 162, 168–170
    - pathophysiology of quality control, 60
    - pathway of misfolded protein degradation, 36
    - 26S proteasome, 59
    - ubiquitination language, 57–58
    - ubiquitin conjugation, 56–57
  - UCH-L1 gene, 244–246
  - Unfolded protein response (UPR)
    - absence in  $\alpha$ 1-antitrypsin deficiency, 188–189
    - aging and, 73
    - branches of, 298–299
    - described, 298–299
    - endoplasmic reticulum and, 73, 148–151
    - mitochondria-specific, 162, 172–173
    - prolonging, 326–327
    - in retinal degeneration, 298–301
      - ABCA4 mutations, 300–301
      - ELOVL4 mutations, 300
      - mild response as protective, 301
      - phosphodiesterase 6 (PDE6) mutations, 300
      - in photoreceptors, 299–301
      - in retinal pigment epithelium (RPE), 301
      - retinoschisin, 301
      - rhodopsin mutations, 299–300
  - Unfolded protein titration model, 18
  - UPR. *See* Unfolded protein response (UPR)
  - UPS. *See* Ubiquitin/proteasome system (UPS)
- V**
- Variation, natural genetic, 96–97
  - Vertex 809/Vertex 770, 288–289, 293
  - Voltage-dependent anion channel (VDAC), 154, 155
- Y**
- Yeast prions, 260, 271